VS 8(Compound VS 8)是一种有效的口服 VEGFR-2 抑制剂,具有显著的抗血管生成 (anti-angiogenic) 作用,可诱导癌细胞凋亡 (apoptosis) 和迁移,并对 CSCs(癌症干细胞)具有活性。
产品编号: MS-T76068 CAS No.: 2471865-38-8 分子式: C26H20F3N3O3 分子量: 479.45
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

VS 8(Compound VS 8)是一种有效的口服 VEGFR-2 抑制剂,具有显著的抗血管生成 (anti-angiogenic) 作用,可诱导癌细胞凋亡 (apoptosis) 和迁移,并对 CSCs(癌症干细胞)具有活性。

生物实验数据

生物活性 VS 8 (Compound VS 8) is a potent oral VEGFR-2 inhibitor with significant anti-angiogenic effects that induces cancer cell apoptosis and migration and is active against CSCs (cancer stem cells).
IC50 & Target

VEGFR-2

 

体外研究
(In Vitro)

VS 8 (Compound VS 8) (0.01-100 µM, 24 h) shows potent anti-proliferative activity against MCF-7, MDA-MB-231, Hep G2, and HUVECs cells.
VS 8 induces early apoptosis in MDA-MB-231 (1413 nM, 72 h), Hep G2 (257.80 nM, 24 h), and HUVECs (1954 nM, 24 h) cells.
VS 8 is shown to be a pro-oxidant molecule that enhances the ROS level in Hep G2 cells.
VS 8 inhibits wound healing and migration of MCF-7 cancer cells.
VS 8 downregulates human vascular endothelial growth factor (hVEGF) and hVEGFR-2 expression in HUVECs.
VS 8 (257.80 nM, 48 h) arrests cell cycle at ‘G0/G1’ and ‘S’ phase in CD44+ and CD133+ CSCs, respectively.
VS 8 inhibits TGF-β-induced epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma by the upregulation of E-cadherin and the suppression of vimentin and SNAIL.

Cell Proliferation Assay

Cell Line: MCF-7, MDA-MB-231, Hep G2, and HUVECs cells
Concentration: 0.01, 0.1, 1, 10, 50, and 100 µM
Incubation Time: 24 h
Result: Showed significantly potent anti-proliferative activity against all the selected cell lines in a dose-dependent manner, with IC50 values of 953.30, 1413, 257.80, and 1954 nM against MCF-7, MDA-MB-231, Hep G2, and HUVECs cells.

Apoptosis Analysis

Cell Line: MDA-MB-231, Hep G2, and HUVECs cells
Concentration: 1413, 257.80, and 1954 nM for MDA-MB-231, Hep G2, and HUVECs cells, respectively.
Incubation Time: 72 h for MDA-MB-231 cells; 24 h for Hep G2 and HUVECs cells
Result: Resulted in high population of early apoptotic MDA-MB-231 cells (68.34 ± 0.18%). A significant increase in % apoptotic index (~86.66%) was observed in Hep G2 cells. The percentage of early apoptotic cells were found to be ~37.53% in HUVECs cells.

Cell Cycle Analysis

Cell Line: CD44+ and CD133+ CSCs isolated from Hep G2 cells
Concentration: 257.80 nM
Incubation Time: 48 h
Result: Arrested cell cycle at ‘G0/G1’ and ‘S’ phase in CD44+ and CD133+ CSCs, respectively.
体内研究
(In Vivo)

VS 8 inhibits angiogenesis in the chick chorioallantoic membrane without oral toxicity.

Animal Model: Male Wistar rats (180-220 gm)
Dosage: 5 mg/kg
Administration: Oral administration (Pharmacokinetic Analysis)
Result: Pharmacokinetic parameters for VS 8 in rats after administration of oral dose (5 mg/ kg)
Pharmacokinetic parameters Unit Value
Cmax μg/mL 39.7193 ± 0.36
Tmax hrs 6 ± 0
AUC(0-72) mg/mL*hrs 621.3236 ± 1.843
AUC(0-∞) mg/mL*hrs 625.2219 ± 1.864
AUMC(0-∞) (mg/mL*hrs2) 8929.284 ± 72.85
MRT hrs 14.2817 ± 0.102
t1/2 hrs 11.9277 ± 0.324

Data represented as mean ± SD (n = 3); t1/2, Half-Life; Cmax, Maximum Observed Concentration; Tmax, Maximum Observed Time; AUC, Area Under Curve; AUMC Area Under Movement Curve, MRT, Mean Residence Time.

化学信息

分子量 479.45
分子式 C26H20F3N3O3
CAS No. 2471865-38-8

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础